Adult patients who miss a dose of Tresiba® should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1
A long-acting basal insulin indicated to improve glycemic control in patients 1 year of age and older with diabetes.1
aFor up to 24 months. Maximum savings of $500 per prescription. Eligibility and other restrictions apply.
bYou must be a licensed practitioner who can legally prescribe medication in your state. (Request for product samples is limited to 1 request per health care professional.)
BEGIN: Low Volume study design
A 26-week, randomized, open-label, multicenter trial in insulin-naïve adults with type 2 diabetes comparing the efficacy and safety of once-daily Tresiba® U-200 (n=228) and once-daily insulin glargine U-100 (n=229) + metformin +/- dipeptidyl peptidase-4 (DPP-4) inhibitor. Basal insulin was titrated weekly to a fasting plasma glucose (FPG) target of 70 to 90 mg/dL according to mean prebreakfast self-measured blood glucose (SMBG) values (mean of 3 consecutive days). Primary endpoint was change in A1C from baseline after 26 weeks of treatment (noninferiority margin of 0.4% was met). Tresiba® A1C reduction from baseline at end of study: 1.18%.1,2
Schedules change. For adults, dose timing can too.
Once-daily Tresiba® offers continued efficacy for your adult patients
even if a dose is delayed or schedules change.1
Adult patients who miss a dose of Tresiba® (insulin degludec 100 Units/mL, 200 Units/mL) should inject their daily dose during waking hours upon discovering the missed dose, then continue with their regular dosing schedule. Ensure that at least 8 hours have elapsed between Tresiba® injections.1